Ying Huang

Biogen Inc (NASDAQ: BIIB) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral rating on Biogen with a $348 price target. H.C. Wainwright analyst Andrew Fein reiterated a Buy...

Opposition to the buyout deal Bristol-Myers Squibb Co (NYSE: BMY) negotiated with Celgene Corporation (NASDAQ: CELG) in January is rising and could potentially impede the M&A momentum seen in the biotech space this year. What Happened Wellington Management Co, which owns an 8.3-percent stake...

Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares are poised to extend their losses to the fifth straight session, with the most recent trigger being the adcom meeting on its multiple myeloma drug. The Analysts Wedbush analyst David Nierengarten maintained an Outperform rating on KaryoPharm...

Gilead Sciences, Inc. (NASDAQ: GILD), which focuses on antiviral drugs, reported below-consensus fourth-quarter earnings per share Monday, sending its shares down.  The Analysts Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating on the shares of Gilead and trimmed the...

Puma Biotechnology Inc (NASDAQ: PBYI) released positive top-line results for its lead drug candidate PB272, or Nerlynx, which is being evaluated for treating HER2+ metastatic breast cancer patients who have failed two or more prior lines of HER2+ directed treatments. Nerlynx along with capecitabine...

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news.  The Analysts Raymond James' Laura Chico maintained a Market...

Esperion Therapeutics Inc (NASDAQ: ESPR) stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. While the company hit its primary endpoints with the trial, patients in the test group experienced a higher...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)’s promising Praluent trial outcomes — and an effective marketing strategy to expand access to the drug — could give the company a strong competitive standing in the cardiovascular drug market, according to Bank of America Merrill Lynch...

Gilead Sciences, Inc. (NASDAQ: GILD) announced fourth-quarter results Tuesday that revealed better-than-expected top- and bottom-line numbers — but the guidance was lackluster. The Analyst Bank of America Merrill Lynch analyst Ying Huang reiterated a Neutral rating on Gilead shares and...

Few would call the biotech sector as exciting as the "FAANG" group. But throughout 2017, investors who completely ignored biotech stocks missed out on strong gains. The Nasdaq Biotechnology index outperformed the S&P 500 index throughout the year. The Analyst Bank of America...

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares have crashed over the past five trading days, falling 11.54 percent to a low of $95.17 on November 20. Ying Huang of Bank of America Merrill Lynch has maintained a Buy rating on the company, with a price objective of $165. With the share...

While all investors are likely concerned about the fallout from a potential FOMC interest rate hike as early as September, perhaps no demographic of the investing world is more concerned than biotech shareholders. Biotech stocks have long been seen as high-risk/high-reward stocks. Therefore,...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading higher by more than 4 percent Wednesday after the company reported better-than-expected earnings for its second quarter. Here are opposing views of what two of Wall Street's top analysts are saying. Bank Of America: Long-Term...